gms | German Medical Science

57th Annual Meeting of the German Society of Neurosurgery
Joint Meeting with the Japanese Neurosurgical Society

German Society of Neurosurgery (DGNC)

11 - 14 May, Essen

LOH 1p/19q analysis from stereotactic serial biopsies in newly diagnosed low grade glioma: feasibility and clinical relevance

LOH 1p/19q Analyse aus stereotaktischen Serien-Biopsien bei neu diagnostizierten niedergradigen Gliomen: Machbarkeit und klinische Relevanz

Meeting Abstract

  • corresponding author J. Mehrkens - Neurochirurgische Universitätsklinik, Ludwig-Maximilians-Universität München
  • E. Grasbon-Frodl - Institut für Neuropathologie, Klinikum Großhadern, Ludwig-Maximilians-Universität München
  • H. Kretzschmar - Institut für Neuropathologie, Klinikum Großhadern, Ludwig-Maximilians-Universität München
  • J.C. Tonn - Neurochirurgische Universitätsklinik, Ludwig-Maximilians-Universität München
  • F.W. Kreth - Neurochirurgische Universitätsklinik, Ludwig-Maximilians-Universität München

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. Essen, 11.-14.05.2006. Düsseldorf, Köln: German Medical Science; 2006. DocP 06.76

The electronic version of this article is the complete one and can be found online at:

Published: May 8, 2006

© 2006 Mehrkens et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: Loss of heterozygosity (LOH) 1p/19q might be an important favorable prognostic genetic marker in the complex framework of treatment independent factors in low grade gliomas. With individualized therapeutic approaches based on exact histopathologic and molecular diagnosis being crucial, the present study was performed to analyze 1. the feasibility of determining LOH 1p/19q from stereotactic biopsies (volume: 1 mm3), 2. the unknown incidence of LOH 1p/19q in non-oligodendral low grade gliomas and 3. the possible intratumoral heterogeneity of this marker.

Methods: In patients with suspected primary low grade glioma on MRI, a stereotactic serial biopsy with a multimodal (CT, MRI, (FET-PET)) 3D-treatment-planning was performed. Besides specimens for intraoperative and definitive histopathologic diagnosis, an average of 3 specimens for LOH 1p/19q analysis was taken from different targets. After DNA extraction, microsatellite analysis for tetranucleotide markers on 1p and 19q was performed. Patients were followed prospectively at 3 month-intervals.

Results: 31 patients with primary low grade glioma (28 astrocytoma, 2 oligoastrocytoma, 1 oligodendroglioma) were included (03/2003-05/2005). LOH 1p/19q was found in 10/28 astrocytomas, 2/2 oligoastrocytomas and in the oligodendroglioma. There was no LOH 1p/19q-heterogeneity within the individual tumors. No patient so far (mean follow-up of 9.5 months) suffered from tumor progression after various treatment strategies (observation in 13 (5 LOH 1p/19q), open resection in 7 (2 LOH 1p/19q), radiotherapy in 3 (2 LOH 1p/19q), chemotherapy (PCV) in 7 (2) and interstitial radiosurgery (I-125-seeds) in 1 (1 LOH 1p/19q) patient(s)).

Conclusions: Analysis of LOH 1p/19q from stereotactic biopsies (1 mm3) is feasible and might add important information for the individual treatment decision. LOH 1p/19q could be detected in a significant number (36%) of non-oligodendral low grade gliomas and in neither of the tumors heterogeneity of this marker was found. Extended follow-up evaluation will be essential to address optimal treatment strategies for those patients harboring this possibly favorable genetic marker.